Ligand Pharmaceuticals (LGND) Exchange Rate Effect (2018 - 2026)
Ligand Pharmaceuticals (LGND) posted Exchange Rate Effect of -$44000.0 for Q1 2026, up 92.54% sequentially from -$590000.0 in Q4 2025, and down 104.16% YoY from $1.1 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Exchange Rate Effect (2018 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Exchange Rate Effect for 6 years, with the latest figure at -$44000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 104.16% year-over-year to -$44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 1213.27% YoY) and the FY2025 annual result came in at $2.4 million, up 301.54% from the prior year.
- Exchange Rate Effect advanced to -$44000.0 in Q1 2026 per LGND's latest filing, from -$590000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $5.2 million in Q3 2024 and troughed at -$4.8 million in Q2 2024.
- A 3-year average of $143125.0 and a median of -$222000.0 in 2025 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 147.6% in 2025, down 107.7% in 2025.
- Over 3 years, Exchange Rate Effect stood at -$1.5 million in 2024, then jumped by 61.89% to -$590000.0 in 2025, then jumped by 92.54% to -$44000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$44000.0, -$590000.0, and -$400000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 39,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39,000.00 |
| Jun 30, 2026 | 39,000.00 |
| Mar 31, 2026 | -44,000.00 |
| Mar 31, 2026 | -44,000.00 |
| Dec 31, 2025 | -590,000.00 |
| Dec 31, 2025 | -590,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Jun 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | -1.55 Mn |
| Dec 31, 2024 | -1.55 Mn |
| Sep 30, 2024 | 5.19 Mn |
| Sep 30, 2024 | 5.19 Mn |
| Jun 30, 2024 | -4.82 Mn |
| Jun 30, 2024 | -4.82 Mn |
| Dec 31, 2020 | 50,000.00 |
| Dec 31, 2020 | 50,000.00 |